Industry
Biotechnology
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Loading...
Open
13.28
Mkt cap
95M
Volume
23K
High
13.77
P/E Ratio
-0.55
52-wk high
24.40
Low
13.03
Div yield
N/A
52-wk low
10.00
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 11:17 am
Portfolio Pulse from Benzinga Newsdesk
September 25, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 10:35 am
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 8:23 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 8:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 6:46 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.